[249] 기타의 호르몬제

 구  분

 세부인정기준 및 방법

사 유

현  행

개  정(안) 

 [249]
Long-acting octreotide 주사제

(품명: 산도스타틴라르주사10밀리그램 등)

허가사항 범위 내에서 투여 시 요양급여 함을 원칙으로 하며, 허가사항 범위를 초과하여 아래와 같은 기준으로 투여하는 경우에는 약값 전액을 환자가 부담토록 함.

1. 허가사항 범위 내에서 투여 시 요양급여를 함을 원칙으로 함.

2. 허가사항 범위(효능ㆍ효과 등)를 초과하여 아래와 같은 기준으로 투여 시에도 요양급여를 인정함.

 임상문헌, 학회의견, 기심의사례 등을 참고하여 허가범위 초과하여 약값 전액본인부담하는 항목을 요양급여로 인정함.

 - 아 래 -

○ 카르시노이드 증후군을 나타내지 않으나 옥트레오스캔 양성 또는 생물표지자(Biomarkers)가 상승된 수술이 불가능한 전이성 진행성 내분비 종양 환자에게 투여 시

 - 아 래 -

○ 카르시노이드 증후군을 나타내지 않으나 옥트레오스캔 양성 또는 생물표지자(Biomarkers)가 상승된 수술이 불가능한 전이성 진행성 내분비 종양 환자에게 투여 시

 ※ 관련근거

․AHFS Drug Information (2006) p.3742

․Cinical Oncology 3rd (2004) p.1635

․NCCN Clinical Practice Guidelines in Oncology V.3.2017, Neuroendocrine Tumors

․Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide, Annals of Oncology 11:1127-1130, 2000

· Harrison's Principles of Internal Medicine, 20e

· Comprehensive Clinical Nephrology, 6th ed, 2019

· Current Diagnosis & Treatment: Emergency Medicine, 8e, 2017

· Pharmacotherapy: A pathophysiologic Approach, 10e, 2017

· KDIGO Anemia in Chronic Kidney Disease, 2012

· Chronic kidney disease: managing anaemia. NICE guideline Published: 3 June 2015

· Mikhail A et al. Renal association clinical practice guideline on anaemia od Chronic Kidney Disease, BMC Nephrology (2017) 18:345

· Locatelli F et al. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice(ERBP), 2008

· Yamamoto H et al. 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease

· Collister D, Komenda P et al. The Effect of Erythropoietin-Stimulating Agents on Health-Related Quality of Life in Anemia of Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2016 Apr 5;164(7):472-8.

· Palmer SC, Saglimbene V et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev. 2014 Dec 8;(12):CD010590.

· Johansen KL, Finkelstein FO et al. Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients. Nephrol Dial Transplant. 2012 Jun;27(6):2418-25.

· Palmer SC, Navaneethan SD et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010 Jul 6;153(1):23-33.

· Inrig JK, Barnhart HX et al. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis. 2012 Sep;60(3):390-401.

· Patel M, Thimons DG et al. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting. J Am Med Dir Assoc. 2012 Mar;13(3):244-8.